TTR and poikiloderma with neutropenia: Herein, we utilized differential precipitation of proteins (DiffPOP), proteomics, and peptidomics to comprehensively profile the plasma proteomic differences in heterozygotic V30M ATTRv-PN patients and V30M TTR carriers and the changes in V30M ATTRv-PN patients treated with tafamidis (20 mg once a day) after up to 60 months to identify additional proteome markers of ATTRv-PN and the response of the biomarkers to treatment.